Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Horizon Therapeutics
Horizon Therapeutics
Activities:
Manufacturing
Ingredients
Pharmaceutical
X
LinkedIn
Trending Articles
Rentschler Biopharma appoints Patrick Cushing as VP Operations for US subsidiary
The novel position will require Dr Cushing to manager operations at the Miford, MA facility in the US
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Johnson & Johnson submits regulatory application for Tremfya to the European Medicines Agency
The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn’s disease, which each achieved their primary...
Amolyt receives FDA fast track designation for hypoparathyroidism drug
The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Regulatory
Horizon Pharma to leverage Medidata Clinical Cloud and eTMF
Medidata will increase efficiency for Horizon Pharma by managing its clinical research on a unified cloud platform
Finance
Horizon Pharma pursues Depomed with US$3bn hostile bid
Aims to combine its rare disease business with Depomed's pain treatments
Finance
Horizon Pharma to purchase Hyperion Therapeutics for US$1.1bn
Expands orphan drug business with the addition of two treatments for rare metabolic conditions
Finance
Horizon Pharma to buy Vidara Therapeutics International for US$660m
US company aims to take advantage of lower tax rates in Ireland
Subscribe now